12 active not recruiting, 7 recruiting, 6 not yet recruiting, 5 unknown. 34 Phase 2, 11 Phase 1.
Follow Turcot syndrome: new trials by email Literature Review of Turcot syndrome trials Research Report on Turcot syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) DES-1357 - Metastatic Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Not yet recruiting | D. E. Shaw Research, LLC | 88 | 2026-12-03 | 2026-09-08 |
| Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer Iparomlimab and Tuvonralimab (QL1706) - Endometrial Cancer, Immunotherapy | Phase 2 | Not yet recruiting | Women's Hospital School Of Medicine Zhejiang University | 30 | 2026-03-01 | 2026-01-27 |
| Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer Nivolumab, Ipilimumab (1mg/kg), PULSAR - Colorectal Cancer (MSI-H) | Phase 2 | Not yet recruiting | Fudan University | 114 | 2026-02-01 | 2026-02-11 |
| Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma Immunotherapy, Induction chemotherapy, D2 radical gastrectomy - Gastric / Gastroesophageal Junction Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 15 | 2026-01-31 | 2026-01-07 |
| Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study Adebrelimab, XELOX, SHR-8068 - Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 30 | 2026-01-30 | 2026-01-27 |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors EIK1005, pembrolizumab (KEYTRUDA® ) - Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Eikon Therapeutics | 160 | 2026-01-20 | 2026-10-30 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK5460025 - Neoplasms, Colorectal, Neoplasms | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 47 | 2025-10-20 | 2026-09-16 |
| Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study. Pembrolizumab Injection [Keytruda], Watch-and-wait approach, Surgery - Colon Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 60 | 2025-09-01 | 2025-06-13 |
| Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer Toripalimab plus celecoxib, Non-operative management, Curative-intent surgery - Colorectal Cancer, Microsatellite Instability High | Phase 2 | Recruiting | Sun Yat-sen University | 105 | 2025-06-01 | 2026-05-22 |
| A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors GSK4418959, PD-1 inhibitor - Neoplasms, Colorectal, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 14 | 2024-12-13 | 2026-02-02 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI] - Endometrial Cancer Stage I, Mmr Deficiency | Phase 2 | Recruiting | Queensland Centre for Gynaecological Cancer | 10 | 2024-08-01 | 2024-12-03 |
| Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer Camrelizumab - Colon Cancer, Mismatch Repair Deficiency | Phase 2 | Active not recruiting | Peking Union Medical College Hospital | 18 | 2024-01-01 | 2026-07-21 |
| Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody - Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Unknown | LiuYing | 22 | 2023-06-20 | 2023-06-22 |
| Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma Toripalimab, Oxaliplatin, S1 - Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction | Phase 2 | Recruiting | Yu jiren | 90 | 2023-05-31 | 2023-07-25 |
| Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer Cadonilimab - Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR) | Phase 1 / Phase 2 | Active not recruiting | Sun Yat-sen University | 28 | 2023-02-07 | 2026-06-24 |
| T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors Pembrolizumab, E7777 - Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | Alexander B Olawaiye, MD | 25 | 2022-09-30 | 2026-05-29 |
| Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Neoadjuvant therapy with PD-L1 inhibitor - Colorectal Cancer, Mismatch Repair-deficient (dMMR) | Phase 2 | Unknown | Third Affiliated Hospital, Sun Yat-Sen University | 26 | 2022-05-05 | 2022-05-12 |
| Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin Atezolizumab, IMM-101 - Colorectal Cancer | Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 80 | 2021-12-10 | 2025-06-15 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
Showing 20 of 34. Sign in to see all of them.
Colorectal Neoplasms (18) · Endometrial Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasm Metastasis (5) · Carcinoma, Renal Cell (4) · Colonic Neoplasms (4) · Melanoma (4) · Microsatellite Instability (4) · Stomach Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Merkel Cell (3) · Mesothelioma, Malignant (3) · Rectal Neoplasms (3) · Carcinoma, Ovarian Epithelial (2)
Neoplasms by Site (29) · Neoplasms (27) · Digestive System Diseases (22) · Digestive System Neoplasms (22) · Gastrointestinal Diseases (22) · Gastrointestinal Neoplasms (22) · Intestinal Diseases (21) · Intestinal Neoplasms (21) · Colonic Diseases (20) · Rectal Diseases (19) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Genital Diseases (9)
Nivolumab (7) · pembrolizumab (6) · Neoadjuvant Therapy (3) · avelumab (3) · toripalimab (3) · Celecoxib (2) · Immune Checkpoint Inhibitors (2) · Ipilimumab (2) · Oxaliplatin (2) · atezolizumab (2) · durvalumab (2) · ALT-803 (1) · Bevacizumab (1) · Capecitabine (1) · Chemotherapy, Adjuvant (1)
Sun Yat-sen University (3) · GlaxoSmithKline (2) · National Cancer Institute (NCI) (2) · Shanghai Zhongshan Hospital (2) · 7 Hills Pharma, LLC (1) · AIO-Studien-gGmbH (1) · Alexander B Olawaiye, MD (1) · Asan Medical Center (1) · D. E. Shaw Research, LLC (1) · Eikon Therapeutics (1) · Fudan University (1) · GERCOR - Multidisciplinary Oncology Cooperative Group (1) · ImmunityBio, Inc. (1) · Institut Bergonié (1) · LiuYing (1)
United States (16) · China (9) · France (6) · Australia (5) · Spain (5) · South Korea (4) · Canada (3) · Germany (3) · Belgium (2) · Italy (2) · Japan (2) · Netherlands (2) · Portugal (2) · Austria (1) · Denmark (1)
Alexander Olawaiye, MD (1) · Andreas Obermair, Professor (1) · Arash Yavari, MBBS (1) · Daniel A Morgenstern, MB BChir PhD (1) · David S Hong (1) · Dung Le, MD (1) · Jeannie Hou, MD (1) · Jiren Yu (1) · Julius Y Strauss, M.D. (1) · Lionel Lewis, MA, MB.Bch, MD (1) · Matthew B. Rettig, MD (1) · Meng Qiu, M.D. (1) · Nilofer S Azad (1) · Nilou Mobashery, MD (1) · Nina Merchant (1)
PMID 31399043, PMID 31765263, PMID 33535600, PMID 34606846, PMID 34688374, PMID 34965951, PMID 34998048, PMID 35235414, PMID 35352512, PMID 37409565, PMID 38022532, PMID 39886125, PMID 39955187, PMID 40204996, PMID 40579407, PMID 40627813, PMID 42385761
2016 (2), 2023 (1), 2025 (1), P30CA046934 (1), P50CA062924 (1), U10CA180820 (1), U24CA196172 (1)